InvestorsHub Logo
Followers 23
Posts 2188
Boards Moderated 0
Alias Born 03/18/2013

Re: None

Sunday, 07/06/2014 2:25:29 PM

Sunday, July 06, 2014 2:25:29 PM

Post# of 426185
Whatalane & JL, I don't disagree with your calcs. You're close enough for Gubmint work as they say. Makes sense now that we've topped 8k per week equates to 32k scripts per month. I did get an exact cost for Vascepa from Express Scripts for my 90 script. Apparently, my provider pays approximately $488 for my 90 script which comes to $1.36 per capsule. I pay $120 co-pay. So, unless I'm mistaken this provides revenues of $5.3m per month x 12= $63m annual revs. If break even is approximately $132m annual then V scripts need to be more than double the current rate. Or $11m revs per month or 66,415 scripts per month or 16,600 scripts per week. This is very doable this year. Especially when we get FDA issues cleared up. If Lovaza can sell 90k per week, V can do it too with the right decisions being made. Vascepa fortunes have to change eventually. The tsunami wave is coming.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News